Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2010  |  Volume : 6  |  Issue : 3  |  Page : 249-254


Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

Correspondence Address:
Ajay Gupta
P-41, South Extension-2, New Delhi - 110 049
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0973-1482.73330

Rights and Permissions

Gefitinib is an orally active, highly selective, reversible inhibitor of the tyrosine kinase domain associated with the epidermal growth factor receptor (EGFR). EGFR gene mutations, never smoking status, Asian origin and adenocarcinoma histology are associated with good clinical responses to geftinib. Geftinib has generally been tried in the setting of chemotherapy refractory disease in patients who have failed at least one line of therapy. Trials are exploring use of geftinib as first line therapy in patients harboring EGFR mutations and also in the elderly. The most exciting feature of geftinib use is its potential for Lazarus responses in patients with poor performance status. Its use is associated with little toxicity. The success of geftinib suggests that it is important to understand the basic mechanisms underlying lung cancer in order to evolve better therapies. The review has been prepared after conducting extensive PubMed and Medline search for related articles.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded737    
    Comments [Add]    
    Cited by others 8    

Recommend this journal